Evidence map›Paper›PMID 37514189›Full record

ReviewPharmaceutics2023

Metal-Based Nanoparticles for Cancer Metalloimmunotherapy.

Ivan Hardianto Suliman, Kidong Kim, Weihsuan Chen, Yubin Kim, Jeong-Hyun Moon, Sejin Son, Jutaek Nam

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Metallic nanomedicine in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025
    Review
  5. Embracing cancer immunotherapy with manganese particles.Cellular oncology (Dordrecht, Netherlands) · 2025
    Review
  6. Article
  7. Article
  8. Dual-modality immune nano-activator harnessing MnJournal of nanobiotechnology · 2025
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ivan Hardianto SulimanCollege of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.ORCID 0000-0002-6527-186X
Kidong KimDepartment of Biological Sciences, Inha University, Incheon 22212, Republic of Korea.ORCID 0009-0008-7130-5115
Weihsuan ChenDepartment of Biological Sciences, Inha University, Incheon 22212, Republic of Korea.
Yubin KimDepartment of Biological Sciences, Inha University, Incheon 22212, Republic of Korea.
Jeong-Hyun MoonDepartment of Biological Sciences, Inha University, Incheon 22212, Republic of Korea.
Sejin SonDepartment of Biological Sciences, Inha University, Incheon 22212, Republic of Korea.
Jutaek NamCollege of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.
Inha University · KRChonnam National University · KR

Funding

Chonnam National University research grantInha University research grantNational Research Foundation of Korea 2022R1A2C1006643National Research Foundation of Korea 2022R1A4A3026347
6 · The paper itself

Abstract

Although the promise of cancer immunotherapy has been partially fulfilled with the unprecedented clinical success of several immunotherapeutic interventions, some issues, such as limited response rate and immunotoxicity, still remain. Metalloimmunotherapy offers a new form of cancer immunotherapy that utilizes the inherent immunomodulatory features of metal ions to enhance anticancer immune responses. Their versatile functionalities for a multitude of direct and indirect anticancer activities together with their inherent biocompatibility suggest that metal ions can help overcome the current issues associated with cancer immunotherapy. However, metal ions exhibit poor drug-like properties due to their intrinsic physicochemical profiles that impede in vivo pharmacological performance, thus necessitating an effective pharmaceutical formulation strategy to improve their in vivo behavior. Metal-based nanoparticles provide a promising platform technology for reshaping metal ions into more drug-like formulations with nano-enabled engineering approaches. This review provides a general overview of cancer immunotherapy, the immune system and how it works against cancer cells, and the role of metal ions in the host response and immune modulation, as well as the impact of metal ions on the process via the regulation of immune cells. The preclinical studies that have demonstrated the potential of metal-based nanoparticles for cancer metalloimmunotherapy are presented for the representative nanoparticles constructed with manganese, zinc, iron, copper, calcium, and sodium ions. Lastly, the perspectives and future directions of metal-based nanoparticles are discussed, particularly with respect to their clinical applications.

Indexed as

cancerimmune cell regulationimmunotherapymetal-based nanoparticlemetal ionmetalloimmunotherapy

Identifiers

PMID37514189
PMCPMC10385358
OpenAlexW4385226757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.